Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: ADEL 7 who wrote (67)	11/4/1998 12:35:00 AM
From: yosi s	Respond to of 1386

Adel You do not have to wait for your daughter to enter college for Pharmos to do well. I have stated in the past that it takes at least six months to see where Prescription for Alrex and Lotemax are going. And that is from the time of launch. That will take us into first Q of 99. By that time Revenues will form part of valuation. As for now Pharmos has enough money to last 10 months. By than revenues should be further up. and Alrex and Lotemax should be available in Europe. Partner for HU 211 should be signed and money given as well. I would not speculate when Pharmos will reach 20$. We can do that once Partner is in and terms of deal are known, and HU 211 is past phase 3. But as oppose to marketing Alrex and Lotemax where Pharmos as to compete with numerous medication including generics. HU 211 will be a first in TBI in a field where many pharmaceutical failed. So it will get a lot of press just for that. The marketing will be a lot easier. And the market penetration a lot faster. Until than Pharmos has room to grow. As for the stock price. I just wonder what will happened once all those preferred shares are converted. I think it is an event worth while watching for.